Section Arrow
Quote
SPRO.NASDAQ
- Spero Therapeutics
Quotes are at least 15-min delayed:2026/04/11 04:10 EDT
Regular Hours
Last
 2.67
-0.11 (-3.96%)
Day High 
2.8 
Prev. Close
2.78 
1-M High
2.8 
Volume 
786.98K 
Bid
2.6
Ask
2.75
Day Low
2.625 
Open
2.8 
1-M Low
2.21 
Market Cap 
160.94M 
Currency 美元 
P/E 18.66 
%Yield -- 
10-SMA 2.49 
20-SMA 2.49 
50-SMA 2.37 
52-W High 3.22 
52-W Low 0.57 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.15/-0.84
Enterprise Value
161.88M
Balance Sheet
Book Value Per Share
1.02
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
59.62M
Operating Revenue Per Share
0.93
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
CUECue Biopharma0.5019+0.209+71.36%-- 
QNCXQuince Therapeutics0.1363+0.0126+10.19%-- 
VRAXVirax Biolabs Group Limited0.1041-0.0308-22.83%-- 
ZNTLZentalis Pharmaceuticals6.61+2.19+49.55%-- 
IOVAIovance Biotherapeutics3.7-0.31-7.73%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.